Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control
- Compare the overall survival of patients with unresectable hepatocellular carcinoma
treated with Sho-saiko-to after ablation therapy with embolization vs historical
- Compare the liver function and alpha fetoprotein levels in patients treated with this
drug vs historical control patients.
- Compare the intervention-free survival in patients treated with this drug vs historical
OUTLINE: Beginning within 1 week after the first course of ablation therapy with
embolization, patients receive oral Sho-saiko-to three times daily. Treatment with
Sho-saiko-to continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study within 18-24
Primary Purpose: Treatment
Ronald DeMatteo, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|